Physician profile
Christopher Patrick Depalo
NPI 1760438238
$1,352.26
in general payments reported to CMS, 2019-2025
13 companies · $382 in 2025
The $382 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $50.41 · 2021: $90.54 · 2022: $205 · 2023: $92.16 · 2024: $49.59 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $523.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $259.34 | 2022-2025 | Idosetr |
| Abbvie INC. | $192.37 | 2022-2025 | Durysta |
| Aerie Pharmaceuticals, INC. | $179.37 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $161.72 | 2019-2021 | |
| Alcon Vision LLC | $148.29 | 2019 | |
| Sun Pharmaceutical Industries INC. | $83.35 | 2020-2022 | |
| Rxsight INC | $75.05 | 2023 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal) |
| Novartis Pharmaceuticals Corporation | $72.68 | 2021-2022 | |
| Allergan, INC. | $66.96 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $59.30 | 2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $19.40 | 2024 | Miebo |
| Shire North American Group INC | $17.66 | 2019 | |
| Astellas Pharma US INC | $16.77 | 2025 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Depalo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.